tirzepatide surmount-1 nejm 2022 weight loss percent First head-to-head trial compares and semaglutide - Results are in! Semaglutide vs. Tirzepatide for Obesity

At Mind Matters Psychiatry & Weight Loss, our goal is to provide patients with evidence-based, personalized care, not hype

Galawesh T, Goljameen Midhat A, Ozdan G

You may lose more weight

The participants also experienced improvements in their metabolic health, such as better control of blood sugar levels

With a rapidly growing research portfolio, my peer-reviewed journal publications have now reached a remarkable Cumulative Impact Factor of 50.4, pushing directly toward the major milestone

Despite the launch of eight biosimilars within the first six months, Humira retained substantial unit market share through 2023 because AbbVie had pre-negotiated deep rebate arrangements with PBMs and insurers that effectively paid for exclusive or preferred formulary placement